Cathepsin D (EC 3.4.23.5) is a lysosomal protease suspected to play important roles in protein catabolism, antigen processing, degenerative diseases, and breast cancer progresson. Determination of the crystal structures of cathepsin D and a complex with pepstatin at 2.5 A resolution provides insights into inhibitor binding and lysosomal targeting for this two-chain, N-glycosylated aspartic protease. Comparison with the structures of a complex of pepstatin bound to rhizopuspepsin and with a human renin-bihbitor complex revealed differences in subsite structures and inhibitor-enzyme interactions that are consistent with affnity differences and structure-activity relationships and suggest strategies for fmetuning the specificity of cathepsin D inhibitors. Mutagenesis studies have identified a phosphotransferase recognition region that is required for oligosaccharide phosphorylation but is 32 A distant from the N-domain glycosylation site at Asn-70. Electron density for the crystal structure of cathepsin D indicated the presence of an N-linked oligosaccharide that extends from Asn-70 toward Lys-203, which is a key component of the phosphotransferase recognition region, and thus provides a structural explanation for how the phosphotransferase can recognize apparently distnt sites on the protein surface.
Cathepsin D (EC 3.4.23.5) is an aspartic protease that is normally found in the lysosomes of higher eukaryotes where it functions in protein catabolism (1). This enzyme is distinguished from other members of the pepsin family (2) by two features that are characteristic of lysosomal hydrolases. First, mature cathepsin D is found predominantly in a twochain form due to a posttranslational cleavage event (1, 3). Second, it contains phosphorylated, N-linked oligosaccharides that target the enzyme to lysosomes via mannose 6-phosphate (M6P) receptors (4, 5) . Phosphorylation involves recognition of both sugar and protein structural determinants by a phosphotransferase enzyme (6, 7) .
Interest in cathepsin D as a target for drug design results from its association with several biological processes of therapeutic significance including lysosomal biogenesis and protein targeting (4, 5) , antigen processing and the presentation of peptide fragments to class II major histocompatibility complexes (8) (9) (10) , connective tissue disease pathology (11) , muscular dystrophy (12) , degenerative brain changes (13, 14) , and cleavage of amyloid precursor protein within senile plaques of Alzheimer brain (15) . Recent studies of primary breast cancers demonstrated that elevated levels of cathepsin D were correlated with an increased risk of metastasis and shorter relapse-free survival (16) . High levels of cathepsin D and other proteases such as collagenase, pro-
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duced in the vicinity of the growing tumor, may degrade the extracellular matrix and thereby promote the escape of cancer cells to the lymphatic and circulatory systems and enhance the invasion of new tissues (17, 18) . The design of potent and specific inhibitors of cathepsin D will aid the further elucidation of the roles of this enzyme in human disease. We previously described the purification and crystallization ofhuman cathepsin D from liver (3); similar studies have been reported recently for cathepsin D isolated from bovine liver (19) and human spleen (20) . We now describe the complete three-dimensional structure of native and pepstatin-inhibited forms of human cathepsin D.W MATERIALS AND METHODS Crystals of native human liver cathepsin D (space group P65; a = b = 125.9 A, c = 104.1 A) were prepared as described (3). The structure was solved by molecular replacement using the program XPLOR-3.0 (21). The crystal structure of porcine pepsin was used as the search molecule (22) . The final R factor was 18.8% for data from 10.0 to 2.5 A resolution for 28 (Fig. 1) : an N-terminal domain (residues 1-188), a C-terminal domain (residues 189-346), and an interdomain, anti-parallel /3sheet composed of the N terminus (residues 1-7), the C terminus (residues 330-346), and the interdomain-linking residues (160-200). The latter region links the pseudo-twofold-related N and C domains (K = 179.30 for the superposition of 19 Ca atom pairs with a rms of 1.5 A), each of which contributes an aspartic acid, Asp-33 and Asp-231, to the active site. The overall structural agreement for the main chain of cathepsin D with the known structures of other mammalian aspartic proteases, human renin (24) This disulfide bridge, which had been predicted from modeling studies of porcine cathepsin D (26) , is within the light chain region and may stabilize the C terminus of the light chain against further proteolytic degradation. There are three proline residues in cathepsin D that refined in a cis-peptide conformation. A cis-peptide bond involving Pro-24 is conserved among all the aspartic proteases except for penicillopepsin, which has a deletion in this region. The other proline residues with cis-peptide bonds are localized within a proline-rich segment, termed the "proline loop," that consists of residues Pro-312, Pro-313, cis-peptide Pro-314, Ser-315, Gly-316, and cis-peptide Pro-317. An analogous structure has been described recently for human renin (24) .
Binding of pepstatin to cathepsin D induced small structural changes in the "flap" region (the (-hairpin structure composed of residues 72-87; Small flap movements due to inhibitor binding have been observed for other aspartic proteases (2). No subdomain displacements were observed in cathepsin D upon inhibitor binding, unlike the case of pepsin (27) and endothiapepsin (28) .
The pepstatin-cathepsin D complex is stabilized by numerous hydrogen bonds between backbone atoms of the inhibitor and both main chain and side chain atoms of the enzyme (Fig. 2A) . The central statine hydroxyl group occupies the position of a water molecule that interacts with the two active-site aspartate residues in the native enzyme structure. In both the native and inhibited structures of cathepsin D, the active-site carboxyl groups are nearly coplanar (rms deviation from the plane < 0.1 A for six atoms). Surprisingly, the P3' statine residue of the inhibitor makes no obvious hydrogen bond with the enzyme despite the presence of several donor and acceptor substituents. His-77 is within 4 A of the statine carboxylate group and may make an electrostatic interaction with the C terminus of the inhibitor.
The inhibitor side chains make extensive van der Waals contacts with the enzyme subsites (Fig. 2B) . In the pepstatin complex, the S3, S2, S1, and S2' subsites are only partially filled and could accommodate bulkier inhibitor substituents at the corresponding positions on the inhibitor. These con- clusions are consistent with structure-activity relationship studies with bovine cathepsin D in which leucine was favored over alanine at P3, 4-amino-3-hydroxy-5-phenylpentanoic acid was favored over statine at P1, and valine was favored over alanine at P2' for synthetic analogues of pepstatin (30) . Studies with human cathepsin D showed that homocysteine was preferred over cysteine at P2 (31) . The Si' and S3' subsites interact with the C-terminal statine substituent. The central statine residue of pepstatin can be considered to be a Pl-Pl' dipeptide isostere of Leu-Gly for which there is no P1' side chain substituent. In the structure of the pepstatincathepsin D complex, the leucine moiety of the P3' statine residue folds back in order to partially occupy the Si' subsite (Fig. 2B) . The (3S)-hydroxyl group on the P1 statine residue contributes substantially to the binding affinity of cathepsin D for pepstatin since the deoxy and (R)-hydroxy analogues were much weaker inhibitors (30) . The structure of the complex reveals that the (S)-OH configuration permits the formation of favorable hydrogen bonds to both Asp-33 and Asp-231, while the R configuration would allow interaction with only Asp-33. Addition of a methyl group to the C-3 position also leads to less favorable binding (30) . Examination of the structure indicates that the binding of a 3-methylstatine analogue would require conformational alterations of the enzyme or inhibitor structures to alleviate bad contacts.
The crystal structure of a complex of pepstatin with the fungal aspartic protease, rhizopuspepsin, has been reported recently (32) (24, 33) reveals that the substratebinding cleft in cathepsin D is wider overall than in renin. Cathepsin D has smaller residues in the S2 (Gly-79 vs. Ser-76) and S4 (Leu-236 vs. Tyr-220) subsites, which leads to larger subsite volumes, which is consistent with the observation that bulky P4 substituents contribute more to the potency of inhibitors for cathepsin D than for pepsin and renin (30, 31) . In renin, the proline loop constitutes part of the S' portion of the substrate-binding cleft. The analogous segment in cathepsin D (residues 312-317) does not make contact with pepstatin (Fig. 1) , despite the fact that this inhibitor extends considerably farther into the S' half of the active site than do the shorter renin inhibitors. The explanation appears to be that renin and cathepsin D exhibit different relative displacements of the small subdomains, which results in about a 3 A wider binding cleft for the latter enzyme.
Phosphotransferase recognition of protein structural determinants and the N-linked oligosaccharide chains at Asn-70 and Asn-199 has been shown to play a key role in the targeting of cathepsin D to lysosomes (4, 5) . Mutagenesis studies using chimeric pepsinogen-cathepsin D molecules defined a minimal protein recognition domain for phosphotransferase consisting of Lys-203 and residues 265-292 (6, 7) . The structure of the phosphotransferase recognition region formed by residues 265-292 in cathepsin D is seen clearly in our electron density maps, and it is topologically similar to a homologous region in pepsinogen that served as the basis for a previous cathepsin D model that has been used to evaluate lysosomal targeting experiments (6, 7 proteins are first superimposed, the above segments are displaced positionally by about 3.0 A rms. This analysis reflects the different relative subdomain displacements for cathepsin D and pepsinogen, which could not have been predicted a priori from the latter structure alone.
Continuous electron density extended from the side chain N81 atom of Asn-70, which corresponds to the N-domain glycosylation site. Four sugar residues that correspond to the core oligosaccharide structure for cathepsin D (6, 7) were fitted to the density (Fig. 3A) . The side chain 081 atom of Asn-70 is hydrogen bonded to the hydroxyl group of Thr-72 in an "asparagine turn" conformation (35, 36) . This interaction stabilizes the Asn-70 side chain and may help to orient the N-linked oligosaccharide. Evidence for C-domain glycosylation at Asn-199 was weak, and a single Nag residue was modeled into the initial Fo -Fc map. We conclude that the oligosaccharide structure at this position is either degraded or disordered.
The crystal structure reveals that Lys-203 and both N-linked oligosaccharides extend from the same face of the protein molecule (Fig. 3B) . Lys-203 is found just below the active-site cleft on the S' side between Asn-70 and Asn-199, which are separated by 36 A. Based on the proposed chemical structure of the phosphorylated oligosaccharide (4, 5) , the Asn-70-linked sugar chain was extended beyond the branch point at Man-403 (Fig. 3A) . In the resulting model structure, the oligosaccharide extends along the protein surface towards Lys-203, and the phosphate oxygens of M6P-406 lie within 5.0 A of the E-amino group of this residue. Our model provides an explanation as to how sites that are 28 A distant on the enzyme surface, Asn-70 and Lys-203, can both contribute to recognition via a flexible oligosaccharide chain. This model is consistent with recent experiments using pepsinogen-cathepsin D chimeras, which demonstrated that oligosaccharides located at considerable distances from the protein recognition domain can still be phosphorylated (37) (38) (39) .
The present results provide a structural basis for further investigations of the targeting of cathepsin D to lysosomes and to the design and synthesis of specific and potent cathepsin D inhibitors. Such inhibitors will help to clarify the role ofcathepsin D in a variety ofimportant disease processes and could lead to the development of a new class of therapeutic agents.
Note Added in Proof: Our crystallographic results are in general accord with predictions of subsite preferences that were based on a recent modeled structure of human cathepsin D (40) .
